Shanghai Pharmaceuticals Holding Co Class H ((SHPMF)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Shanghai Pharmaceuticals Holding Co. Class H (SHPMF) is involved in a significant clinical study titled ‘A Multicenter, Randomized, Controlled, Open Phase II/III Clinical Study to Evaluate the Efficacy and Safety of B007 Versus Cyclosporine in the Treatment of Primary Membranous Nephropathy.’ The study aims to assess the effectiveness and safety of the drug B007 compared to Cyclosporine in treating Primary Membranous Nephropathy, a kidney disorder. This research is crucial as it could lead to improved treatment options for patients suffering from this condition.
The study is testing two interventions: B007, administered via subcutaneous injection on days 1 and 15, and Cyclosporine Capsules, taken orally at 3.5 mg/kg/d. B007 is the experimental drug, while Cyclosporine serves as the active comparator.
The study follows an interventional design with randomized allocation and a parallel intervention model. It is an open-label study with no masking, focusing primarily on treatment efficacy.
The study began on June 17, 2024, with the latest update submitted on March 24, 2025. These dates are important as they indicate the study’s current recruiting status and progress.
For investors, the successful development of B007 could positively impact Shanghai Pharmaceuticals’ stock performance, enhancing investor confidence. In a competitive pharmaceutical landscape, advancements in treatment options can provide a significant edge.
The study is ongoing, with further details available on the ClinicalTrials portal.